poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

BenzingaBenzinga Newsdesk

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

    Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.